FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151809511> ?p ?o ?g. }

• W2151809511 endingPage "53" @default.
• W2151809511 startingPage "46" @default.
• W2151809511 abstract "Purpose: Trastuzumab combined with chemotherapy improves outcomes for women with human epidermal growth factor receptor 2 (HER2) overexpressing advanced breast cancer. We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer. Patients and Methods: Patients with HER2-positive (2+ or 3+ by immunohistochemistry) stage II or III breast cancer received preoperative trastuzumab (4 mg/kg × 1, then 2 mg/kg/wk × 11) in combination with paclitaxel (175 mg/m 2 every 3 weeks × 4). Patients received adjuvant doxorubicin and cyclophosphamide chemotherapy following definitive breast surgery. Clinical and pathologic response rates were determined after preoperative therapy. Left ventricular ejection fraction and circulating levels of HER2 extracellular domain were measured serially. Results: Preoperative trastuzumab and paclitaxel achieved clinical response in 75% and complete pathologic response in 18% of the 40 women on study. HER2 3+ tumors were more likely to respond than 2+ tumors (84% v 38%). No unexpected treatment-related noncardiac toxicity was encountered. Four patients developed grade 2 cardiotoxicity (asymptomatic declines in left ventricular ejection fraction). Baseline HER2 extracellular domain was elevated in 24% of patients and declined with preoperative therapy. Immunohistochemical analyses of posttherapy tumor specimens indicated varying patterns of HER2 expression following trastuzumab-based treatment. Conclusion: Preoperative trastuzumab and paclitaxel is active against HER2 overexpressing early-stage breast cancer and may be feasible as part of a sequential treatment program including anthracyclines. The observed changes in cardiac function merit further investigation. Correlative analyses of HER2 status may facilitate understanding of tumor response and resistance to targeted therapy." @default.
• W2151809511 created "2016-06-24" @default.
• W2151809511 creator A5001562050 @default.
• W2151809511 creator A5006725175 @default.
• W2151809511 creator A5015440359 @default.
• W2151809511 creator A5016380475 @default.
• W2151809511 creator A5019054377 @default.
• W2151809511 creator A5021514634 @default.
• W2151809511 creator A5022756369 @default.
• W2151809511 creator A5042936153 @default.
• W2151809511 creator A5046543148 @default.
• W2151809511 creator A5046623395 @default.
• W2151809511 creator A5052735318 @default.
• W2151809511 creator A5055301443 @default.
• W2151809511 creator A5055568190 @default.
• W2151809511 creator A5057727455 @default.
• W2151809511 creator A5062329369 @default.
• W2151809511 creator A5070245248 @default.
• W2151809511 creator A5091620472 @default.
• W2151809511 date "2003-01-01" @default.
• W2151809511 modified "2023-10-16" @default.
• W2151809511 title "Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study" @default.
• W2151809511 cites W1754020298 @default.
• W2151809511 cites W1933080611 @default.
• W2151809511 cites W1948389446 @default.
• W2151809511 cites W1958704867 @default.
• W2151809511 cites W1977958044 @default.
• W2151809511 cites W2029542561 @default.
• W2151809511 cites W2081271018 @default.
• W2151809511 cites W2104528117 @default.
• W2151809511 cites W2115759102 @default.
• W2151809511 cites W2133764807 @default.
• W2151809511 cites W2139510434 @default.
• W2151809511 cites W2146406055 @default.
• W2151809511 cites W2159459001 @default.
• W2151809511 cites W2162642395 @default.
• W2151809511 cites W2214029008 @default.
• W2151809511 cites W2262955759 @default.
• W2151809511 cites W2318605753 @default.
• W2151809511 doi "https://doi.org/10.1200/jco.2003.03.124" @default.
• W2151809511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12506169" @default.
• W2151809511 hasPublicationYear "2003" @default.
• W2151809511 type Work @default.
• W2151809511 sameAs 2151809511 @default.
• W2151809511 citedByCount "268" @default.
• W2151809511 countsByYear W21518095112012 @default.
• W2151809511 countsByYear W21518095112013 @default.
• W2151809511 countsByYear W21518095112014 @default.
• W2151809511 countsByYear W21518095112015 @default.
• W2151809511 countsByYear W21518095112016 @default.
• W2151809511 countsByYear W21518095112017 @default.
• W2151809511 countsByYear W21518095112018 @default.
• W2151809511 countsByYear W21518095112019 @default.
• W2151809511 countsByYear W21518095112020 @default.
• W2151809511 countsByYear W21518095112021 @default.
• W2151809511 countsByYear W21518095112022 @default.
• W2151809511 countsByYear W21518095112023 @default.
• W2151809511 crossrefType "journal-article" @default.
• W2151809511 hasAuthorship W2151809511A5001562050 @default.
• W2151809511 hasAuthorship W2151809511A5006725175 @default.
• W2151809511 hasAuthorship W2151809511A5015440359 @default.
• W2151809511 hasAuthorship W2151809511A5016380475 @default.
• W2151809511 hasAuthorship W2151809511A5019054377 @default.
• W2151809511 hasAuthorship W2151809511A5021514634 @default.
• W2151809511 hasAuthorship W2151809511A5022756369 @default.
• W2151809511 hasAuthorship W2151809511A5042936153 @default.
• W2151809511 hasAuthorship W2151809511A5046543148 @default.
• W2151809511 hasAuthorship W2151809511A5046623395 @default.
• W2151809511 hasAuthorship W2151809511A5052735318 @default.
• W2151809511 hasAuthorship W2151809511A5055301443 @default.
• W2151809511 hasAuthorship W2151809511A5055568190 @default.
• W2151809511 hasAuthorship W2151809511A5057727455 @default.
• W2151809511 hasAuthorship W2151809511A5062329369 @default.
• W2151809511 hasAuthorship W2151809511A5070245248 @default.
• W2151809511 hasAuthorship W2151809511A5091620472 @default.
• W2151809511 hasConcept C121608353 @default.
• W2151809511 hasConcept C126322002 @default.
• W2151809511 hasConcept C143998085 @default.
• W2151809511 hasConcept C2776694085 @default.
• W2151809511 hasConcept C2776755627 @default.
• W2151809511 hasConcept C2777292972 @default.
• W2151809511 hasConcept C2777982462 @default.
• W2151809511 hasConcept C2778233292 @default.
• W2151809511 hasConcept C2779786085 @default.
• W2151809511 hasConcept C2781303535 @default.
• W2151809511 hasConcept C530470458 @default.
• W2151809511 hasConcept C71924100 @default.
• W2151809511 hasConceptScore W2151809511C121608353 @default.
• W2151809511 hasConceptScore W2151809511C126322002 @default.
• W2151809511 hasConceptScore W2151809511C143998085 @default.
• W2151809511 hasConceptScore W2151809511C2776694085 @default.
• W2151809511 hasConceptScore W2151809511C2776755627 @default.
• W2151809511 hasConceptScore W2151809511C2777292972 @default.
• W2151809511 hasConceptScore W2151809511C2777982462 @default.
• W2151809511 hasConceptScore W2151809511C2778233292 @default.
• W2151809511 hasConceptScore W2151809511C2779786085 @default.
• W2151809511 hasConceptScore W2151809511C2781303535 @default.
• W2151809511 hasConceptScore W2151809511C530470458 @default.

• next